Skip to main content

Men are more prone to mild cognitive impairment

January 26, 2012 - Men are more at risk for mild cognitive impairment, a new study shows. The results were amazing, we refer to the investigators, because women generally have higher rates of dementia."We expect to see a similar proportion of mild cognitive impairment in men and women," said lead researcher Gemma Roberts, MBChB, of the Mayo Clinic in Rochester, Minnesota, Medscape Medical News.The results, published online January 25 in the journal Neurology, suggest that should determine the risk factors for memory loss by sex. Researchers wonder whether there could be even sex-specific strategies to reduce risk.

 
Dr. Rosebud Roberts
In an accompanying editorial, and commended Kenneth Rockwood, MD, of Dalhousie University and Queen Elizabeth Health Sciences Centre in Halifax, Nova Scotia, Canada, and work."The study identified mild cognitive impairment and sub-retroactive, and not of diagnostic criteria retrofitted to talk." Epidemiological data from the Mayo Clinic study of aging "is of interest to one concerned with how changes brain function with age," noted Dr. Rockwood.Investigators studied the population-based cohort of potential Olmsted County, Minnesota. They assessed the population aged between 145,070 حتي 89 years at baseline and at regular intervals to assess the clinical dementia rating scale, health, neurological and neuropsychological.Examiners were blind to previous diagnoses and data that are reviewed at each evaluation to assess the situation according to the knowledge and dissemination standards.The researchers found that the incidence of mild cognitive impairment was prevalent in about 64 per 1000 more than 2 to 4 years. Were evaluated for the vast majority of people are at least 3 times.Cases of mild cognitive impairment (n = 296) *
ResultMenWomenMild cognitive weakness72.457.3Amnestic weakness43.933.3Nonamnestic weakness20.010.9
* Data are number per 1000 patient years."The risk of mild cognitive impairment in men and women together was high in this age group of seniors," said Roberts. "This is worrying given that people are living longer, and mild cognitive impairment may have a significant impact on health care costs if they are not used to increase prevention efforts to reduce the risk."The incidence of mild cognitive weakness is also higher for people with less education than for those who continued their studies (42.6 versus 32.5). This was also the case for mild cognitive weakness nonamnestic - less education, and seemed to put people at a disadvantage in the knowledge later in life (20.3 versus 10.2)."This discovery was not clear from the occurrence of other investigations," noted Dr. Rockwood outside ", but he was not particularly in the prevalence estimates from the Mayo Clinic study."The researchers also found that among people newly diagnosed with mild memory loss, later was diagnosed 12% annually at least once with no cognitive impairment and returned to what appeared to return to the memory of sound. However, Roberts said the majority of people with mild cognitive impairment - about 88% per year - still have symptoms or dementia.The study was funded by the National Institutes of Health, the Robert Wood Johnson Foundation, the Robert H. Smith and Clarice program and Abigail van Buren Alzheimer's disease research, and project Epidemiology of Rochester. Dr. Roberts received research support from the National Institutes of Health and Abbott. Dr. Rockwood receives research support from the Canadian Institutes for Health Research, Nova Scotia Health Research Foundation, and a fellowship from the Alzheimer's Association of Canada. Is president and chief scientific officer of the Iraqi National Congress DementiaGuide and received funding from the Dalhousie Medical Research Foundation, Elan, Wyeth, Bristol Myers Squibb, Eisai, and Pfizer.

Comments

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volum...

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n...